FRX and IRWD Related Headlines
Go Back- Ironwood (IRWD) Updates on Q4 Sales; LINZESS Breaks $19M Mark
- Jefferies Maintains a 'Buy' on Forest Laboratories (FRX); Quickly Moving Into Pole Position
- Cantor Fitzgerald Reiterates a 'Sell' on Ironwood Pharmaceuticals (IRWD); Shares Still Overvalued
- UPDATE: Synergy Pharma (SGYP) Higher on Linzess Approval (IRWD) (FRX)
- FDA Approves IBS-C Treatment Linzess (IRWD) (FRX)
- FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation
- UPDATE: Ironwood (IRWD), Forest (FRX) Win FDA Approval for Linzess
